NCT00391079 - Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS | Biotech Hunter

Enrollment

339

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

September 30, 2008

Conditions

Multiple Sclerosis

Interventions

DRUG

Sativex

"Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg."

DRUG

Placebo

Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.

Trial Locations (6)

T2N 2T9

Multiple Sclerosis Program, Foothills Hospital SSB, Calgary

V6T 2B5

MS Clinic, UBC Purdy Pavilion, Vancouver

B3H 1V8

Dalhousie MS Research Clinic, Halifax

N6A 5A5

London Health Sciences Centre / University Hospital, London

K1H 8L6

Ottawa Hospital General Campus, Ottawa

H3 A 2B4

Montreal Neurological Institute, Montreal